geniVida May Reduce Hot Flashes

PARSIPPANY, N.J.—According to a new study first presented at the Experimental Biology 2009 meeting in New Orleans by Dr. James Elliott, a form of pure genistein reduced the number and duration of hot flashes in peri- and postmenopausal women. The study was conducted by KGK Synergize Inc., London, Ontario, and sponsored by DSM Nutritional Products.

In the multi-center, randomized, double blind, placebo-controlled trial, half of the enrolled women were given placebo capsules, the other half were given capsules of a safe, high-purity, non-plant derived, non-allergenic, patent-protected, proprietary genistein branded as geniVida™ by DSM Nutritional Products. Study measurements included daily hot flashes (frequency, duration and intensity), individual-specific safety factors and adverse events.

According to the clinical study, presented as a poster in the “Late Breaking Abstracts” section of the meeting, women receiving 30 mg/d of geniVida experienced 40 percent fewer hot flashes after eight weeks and 44 percent fewer hot flashes after 12 weeks versus baseline, which became statistically significant versus placebo at 12 weeks. Furthermore, 88.5 percent of women in the geniVida group had a 25-percent or greater reduction in the duration of daily hot flashes versus baseline at 12 weeks, also statistically significant versus placebo. There were no differences between the groups for any of the safety factors or adverse events.

The genistein in geniVida, formerly known as BONISTEIN®, is a branded, pure, non-soy genistein from DSM. It is available in both food- and pharmaceutical-grade and is supported by extensive, published safety studies. geniVida is available in both crystalline and tablet-grade forms.